Pharmaceutical - Women's Health, Asia-Pacific

Filter

Popular Filters

Advaxis out-licenses ADXS-HPV to Biocon for emerging markets

Advaxis out-licenses ADXS-HPV to Biocon for emerging markets

23-01-2014

Indian biotech firm Biocon has entered into an exclusive licensing agreement for US cancer drug developer…

AdvaxisADXS-HPVAsia-PacificBioconIndiaLicensingOncologyPharmaceuticalWomen's Health

Torrent to acquire Indian branded formulations from Elder

13-12-2013

Torrent Pharmaceuticals saw its shares rise 7% to 349 rupees after it said it is acquiring the branded…

Asia-PacificElder PharmaceuticalsIndiaMergers & AcquisitionsNeurologicalPharmaceuticalTorrent PharmaceuticalsWomen's Health

Ablynx and Eddingpharm sign deal to target Chinese osteoporosis market

Ablynx and Eddingpharm sign deal to target Chinese osteoporosis market

18-10-2013

Ablynx has granted an exclusive license to Eddingpharm to develop and commercialize its anti-RANKL Nanobody,…

AblynxAsia-PacificEddingpharmLicensingPharmaceuticalWomen's Health

Phebra gains right to market Syntometrine in Australia

Phebra gains right to market Syntometrine in Australia

27-09-2013

Phebra has signed an exclusive commercial agreement with UK-based pharmaceutical firm Alliance Pharma…

Alliance PharmaAsia-PacificLicensingPharmaceuticalSyntometrineWomen's Health

Japan vaccines briefs: Gardasil and Cervarix; Daiichi Sankyo files NDA

21-06-2013

The Japanese Ministry of Health, Labor and Welfare has decided to withdraw its recommendation for a vaccination…

Asia-PacificCervarixDaiichi SankyoGardasilGlaxoSmithKlineMerck & CoPharmaceuticalRegulationVaccinesWomen's Health

Arzerra and ospemifene NDAs submitted in Japan

02-05-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) and Danish company Genmab A/S (OMX: GEN) have submitted a…

ArzerraAsia-PacificGenmabGlaxoSmithKlineOncologyospemifenePharmaceuticalQuatRx PharmaRegulationShionogiWomen's Health

Parexel

Parexel

Back to top